Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE CardioMEMS, Inc.
Award to be presented at December 5 dinner
ATLANTA, Oct. 29, 2013 /PRNewswire/ -- CardioMEMS, Inc., an Atlanta-based medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, announced today that the company's Chairman of the Board, John Huntz, has been awarded a 2013 Atlanta Business Chronicle Outstanding Directors Award. The awards, presented in partnership with the National Association of Corporate Directors, recognize board directors that have demonstrated the vital leadership and business savvy necessary to help guide their businesses' success.
"I am deeply honored to receive this award," said Mr. Huntz. "Working with CardioMEMS founder and CEO Dr. Jay Yadav and his team to bring the company's innovative and unique technology forward to benefit patients suffering from chronic diseases such as heart failure has been one of the most gratifying challenges in my professional career."
Added Dr. Yadav, "John represents the finest attributes an entrepreneur and CEO could hope for in a board chairman: leadership, experience, vision, fortitude and absolute ethical standards. The last few years have been challenging for many venture capital-backed companies, but through all these years, John has never wavered in his goal to seek what was best for CardioMEMS and its stakeholders."
The 2013 Outstanding Directors Awards will be presented by the Atlanta Business Chronicle on Thursday, December 5, 2013, at the Ritz Carlton Buckhead. Additional information can be found at http://www.bizjournals.com/atlanta/event/88751#eventDetails.
About CardioMEMS, Inc.
CardioMEMS is a medical device company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body. The company's technology platform is designed to improve the management of severe chronic cardiovascular diseases such as aneurysms, heart failure, and hypertension. CardioMEMS miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data, which are critical to the management of patients. The sensors are designed to be permanently implanted into the heart and blood vessels due to their small size, durability and lack of wires and batteries. Using radiofrequency (RF) energy, the sensors transmit real-time data to external electronic readers, which then communicate this information to the patient's physician. CardioMEMS developed this technology based on the belief that frequent, on-demand, real-time monitoring of vital information enables proactive patient management, which holds the promise of reducing hospitalizations, improving a patient's quality of life and delivering more efficient and cost effective health care. More information about CardioMEMS is located at www.cardiomems.com.
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company's products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.
CardioMEMS and the CardioMEMS logo are registered trademarks of CardioMEMS, Inc. Champion is a trademark of CardioMEMS, Inc.
Caution: The Champion Heart Failure Monitoring System is an investigational device limited by federal law to investigational use.
©2012 PR Newswire. All Rights Reserved.